treaatment of hepato renal syndrome
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
treaatment of hepato renal syndrome
Reading File
Finding Sources
Finding Sources
Searching PubMed
"hepatorenal syndrome" AND treatment
Searching the Web
2024 AASLD hepatorenal syndrome acute kidney injury treatment terlipressin albumin guidance
Reading File
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC10524408
Hepatorenal syndrome treatment
Hepatorenal syndrome-acute kidney injury (HRS-AKI) is an emergency in advanced cirrhosis, usually with ascites. It requires hospital management, early hepatology input, and assessment for liver transplantation, the only definitive treatment.
1. Confirm HRS-AKI and correct reversible causes
Before labeling AKI as HRS, clinicians should:
- Stop nephrotoxic drugs, especially NSAIDs, ACE inhibitors/ARBs, and avoid IV contrast where possible.
- Hold diuretics temporarily if volume depletion is possible.
- Look for and promptly treat triggers: spontaneous bacterial peritonitis, other infections, GI bleeding, diarrhea/vomiting, excessive paracentesis without albumin, and shock.
- Exclude obstruction and intrinsic renal injury, including acute tubular necrosis.
- Give an albumin volume challenge when appropriate, commonly 1 g/kg/day of 20-25% albumin, maximum 100 g/day, for 2 days, while carefully checking for pulmonary edema or fluid overload.
2. Vasoconstrictor plus albumin: first-line disease-specific therapy
The usual preferred treatment for confirmed HRS-AKI is terlipressin plus IV albumin. Terlipressin constricts the splanchnic circulation, improving effective arterial volume and renal perfusion. AASLD-based guidance identifies terlipressin plus albumin as the preferred regimen. AASLD-based management review
- Terlipressin: dose depends on local protocol/product labeling. In the US, a commonly used label-based regimen starts at 0.85 mg IV every 6 hours for 3 days, then is adjusted according to serum-creatinine response, for a maximum of 14 days.
- Albumin during treatment: often 20-40 g/day, individualized to volume status. Do not give albumin indiscriminately if there is pulmonary edema or major volume overload. AASLD albumin review
Monitor closely: blood pressure, urine output, serum creatinine, sodium, fluid balance, ischemic symptoms, and oxygen saturation.
Important safety issue: terlipressin may cause serious or fatal respiratory failure and can cause coronary, mesenteric, or peripheral ischemia. Avoid or stop it in hypoxia, worsening respiratory symptoms, or ongoing ischemia; continuous pulse-oximetry monitoring is recommended. The textbook likewise identifies terlipressin plus albumin as a bridge to transplant but warns about respiratory failure. Goldman-Cecil Medicine, Hepatorenal Syndrome section.
3. If terlipressin is unavailable or unsuitable
- Norepinephrine plus albumin: preferred alternative, generally given in an ICU because it requires continuous vasopressor infusion and close hemodynamic monitoring.
- Midodrine plus octreotide plus albumin: an option if neither terlipressin nor norepinephrine can be used, but it is less effective than the other two approaches.
4. Treat complications and consider renal replacement therapy
- Treat sepsis, GI bleeding, hypotension, encephalopathy, and electrolyte disturbances.
- Dialysis/continuous renal replacement therapy is used for standard urgent indications: refractory hyperkalemia, severe acidosis, pulmonary edema/volume overload, or uremic complications.
- Dialysis is mainly a bridge to liver transplant or recovery from a reversible acute insult. It does not correct the underlying circulatory/liver failure.
5. Liver transplantation
Urgently refer or reassess for liver transplantation. Vasoconstrictor therapy may reverse AKI in some people and improve pre-transplant stability, but it does not cure the liver disease. HRS is a transplant-priority condition. Current management review
6. Procedures
- TIPS may help selected patients with portal-hypertension complications, but it is not routine acute treatment for HRS-AKI and is unsuitable in many patients with severe liver failure, encephalopathy, or cardiac dysfunction.
- Extracorporeal albumin dialysis is experimental or highly specialized, not standard first-line management.
Recent evidence
Recent systematic reviews continue to support terlipressin-based therapy for HRS reversal, though respiratory and ischemic adverse effects require careful patient selection and monitoring: 2025 meta-analysis, PMID 40207491 and 2024 systematic review, PMID 39295934.
Practical summary:
Stop precipitants and nephrotoxins -> albumin challenge and infection evaluation -> terlipressin + albumin if HRS-AKI persists -> norepinephrine if terlipressin cannot be used -> dialysis only when indicated/bridge -> urgent transplant evaluation.
Stop precipitants and nephrotoxins -> albumin challenge and infection evaluation -> terlipressin + albumin if HRS-AKI persists -> norepinephrine if terlipressin cannot be used -> dialysis only when indicated/bridge -> urgent transplant evaluation.
This is a shared conversation. Sign in to Orris to start your own chat.